The Diagnostic Value of Contrast-Enhanced Ultrasound and Enhanced CT Combined with Tumor Markers AFP and CA199 in Liver Cancer

Kong, Yunpeng; Jiang, Yan; Sun, Hongmei; Zhou, Shisheng

doi:10.1155/2022/5074571

Cited by 3 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, CEUS has been reported to provide false positive diagnoses of hepatocellular carcinoma in patients with cholangiocarcinoma (11). The detection rate of liver CEUS in detecting early hepatocellular carcinoma has been questioned, and it is still necessary to combine computed tomography (CT), magnetic resonance imaging (MRI), and some biomarkers to improve the detection rate (12). However, some researchers have found that MRI has higher resolution and contrast enhancement function compared to ultrasound and CT, and it is recommended to be the preferred imaging method for hepatocellular carcinoma diagnosis (13).…”

Section: Introductionmentioning

confidence: 99%

Diagnostic value of liver contrast-enhanced ultrasound in early hepatocellular carcinoma: a systematic review and meta-analysis

Zhang¹,

Ma²,

Luo³

2023

J Gastrointest Oncol

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma is the sixth most common cancer in the world, and its incidence rate will continue to increase. Contrast-enhanced ultrasound (CEUS) is feasible as a rapid examination for early hepatocellular carcinoma diagnosis. However, considering the possible causes of false positives caused by ultrasound, its diagnostic value is still controversial. Therefore, the study conducted a meta-analysis to evaluate the application value of CEUS in the early diagnosis of hepatocellular carcinoma.Methods: The PubMed, Cochrane Library, Embase, Ovid Technologies (OVID), China National Knowledge Infrastructure (CNKI), Chongqing VIP Information (VIP), and Wanfang databases were searched to retrieve articles on the use of CEUS for the early diagnosis of hepatocellular carcinoma. The literature quality assessment was performed using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) quality assessment tool. The meta-analysis was performed using STATA 17.0 to fit the bivariate mixed effects model, calculated sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and corresponding 95% CI, summary receiver operating characteristic curves (SROC), area under the curve (AUC), and 95% confidence interval (CI). The publication bias of the included literature was evaluated using the DEEK funnel plot.Results: Ultimately, 9 articles, comprising 1,434 patients, were included in the meta-analysis. The heterogeneity test found that I 2 >50%, using a random effects model. The results of the meta-analysis showed that the CEUS had a combined sensitivity of 0.92 (95% CI: 0.86-0.95), a combined specificity of 0.93 (95% CI: 0.56-0.99), a combined PLR of 13.47 (95% CI: 1.51-120.46), a combined NLR of 0.09 (95% CI: 0.05-0.14), a combined DOR of 154.16 (95% CI: 15.93-1,492.02), a diagnostic score of 5.04 (95% CI: 2.77-7.31), and a combined AUC of 0.95 (95% CI: 0.93-0.97). The correlation coefficient of the threshold-effect analysis was 0.13 (P>0.05). The results of the regression analysis showed that the country of publication (P=0.14) and the size of the lesion nodules (P=0.46) were not sources of heterogeneity.Conclusions: Liver CEUS has an advantage in the early diagnosis of hepatocellular carcinoma, with high sensitivity and specificity, and has clinical application value.

show abstract

Section: Introductionmentioning

confidence: 99%

Diagnostic value of liver contrast-enhanced ultrasound in early hepatocellular carcinoma: a systematic review and meta-analysis

Zhang¹,

Ma²,

Luo³

2023

J Gastrointest Oncol

View full text Add to dashboard Cite

show abstract

In Situ Synthesis of Highly Fluorescent, Phosphorus-Doping Carbon-Dot-Functionalized, Dendritic Silica Nanoparticles Applied for Multi-Component Lateral Flow Immunoassay

Hu,

Ding

2023

Sensors

View full text Add to dashboard Cite

The sensitivity of fluorescent lateral flow immunoassay (LFIA) test strips is compromised by the low fluorescence intensity of the signaling molecules. In this study, we synthesized novel phosphorus-doped carbon-dot-based dendritic mesoporous silica nanoparticles (DMSNs-BCDs) with a quantum yield as high as 93.7% to break this bottleneck. Meanwhile, the in situ growth method increased the loading capacity of carbon dots on dendritic mesoporous silica, effectively enhancing the fluorescence intensity of the composite nanospheres. Applied DMSNs-BCDs in LFIA can not only semi-quantitatively detect a single component in a short time frame (procalcitonin (PCT), within 15 min) but also detect the dual components with a low limit of detection (LOD) (carbohydrate antigen 199 (CA199) LOD: 1 U/mL; alpha-fetoprotein (AFP) LOD: 0.01 ng/mL). And the LOD of PCT detection (0.01 ng/mL) is lower by 1.7 orders of magnitude compared to conventional colloidal gold strips. For CA199, the LOD is reduced by a factor of four compared to LFIA using gold nanoparticles as substrates, and for AFP, the LOD is lowered by two orders of magnitude compared to colloidal gold LFIA. Furthermore, the coefficients of variation (CV) for intra-assay and inter-assay measurements are both less than 11%.

show abstract

Identification of ELOVL3 as a novel prognostic marker for liver cancer

Chen,

Zhou,

Gon

et al. 2023

Acta fac medic Naissensis

View full text Add to dashboard Cite

Introduction. The incidence of liver cancer is increasing globally. Fatty acids in lipid metabolism are associated with cancer risk by maintaining cancer cell membrane structure and transducing cancer signaling, and their increased synthesis promotes tumor growth, angiogenesis, and tumor metastasis. Methods. After identification of the ELOVL3 gene involved in fatty acid metabolism, which is related to the prognosis of liver cancer, its expression level was extracted from The Cancer Genome Atlas (TCGA) database, and differential analysis, survival analysis, clinical correlation analysis and nomogram were used to predict the survival rate. A comprehensive meta-analysis was performed to further evaluate the prognostic value of ELOVL3. Finally, enrichment analysis and immune analysis were performed on the high and low expression groups of ELOVL3 gene to explore the value of ELOVL3 in predicting the prognosis and immunotherapy of liver cancer patients. Results. Patients with high ELOVL3 expression had poor overall survival and progression-free survival. The nomogram and the area under the ROC curve also indicated that the expression of ELOVL3 gene had high accuracy in predicting the survival time of liver cancer patients. The expression of ELOVL3 was significantly different in the early stage of tumor grade, tumor stage and T stage. Enrichment analysis and immunological analysis revealed a variety of information. The immunotherapy analysis also showed that low ELOVL3 was more effective than high ELOVL3 when receiving immunotherapy. Conclusion. The expression of ELOVL3 gene is significantly elevated in HCC and is associated with cancer development and poor prognosis.

show abstract

The Diagnostic Value of Contrast-Enhanced Ultrasound and Enhanced CT Combined with Tumor Markers AFP and CA199 in Liver Cancer

Cited by 3 publications

References 35 publications

Diagnostic value of liver contrast-enhanced ultrasound in early hepatocellular carcinoma: a systematic review and meta-analysis

Diagnostic value of liver contrast-enhanced ultrasound in early hepatocellular carcinoma: a systematic review and meta-analysis

In Situ Synthesis of Highly Fluorescent, Phosphorus-Doping Carbon-Dot-Functionalized, Dendritic Silica Nanoparticles Applied for Multi-Component Lateral Flow Immunoassay

Identification of ELOVL3 as a novel prognostic marker for liver cancer

Contact Info

Product

Resources

About